Michael Kunesh, M.D.
NPI 1962543231 · Ophthalmology Physician · Dayton, OH
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1962543231
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- 35056069 (OH)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
4,775 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Complete Exam of Visual System92014 | 1,308 | $121 |
| Imaging of Optic Nerve92133 | 717 | $35 |
| Photography of the Retina92250 | 521 | $33 |
| Exam of Visual Field With Extended Testing92083 | 507 | $61 |
| Imaging of Retina92134 | 476 | $39 |
| Injection of Drug Into Eye67028 | 283 | $110 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 22 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 2,100 | 512 |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 835 | 251 |
| Brimonidine Tartrate | 609 | 172 |
| Polymyxin B Sulf/Trimethoprimbrand: Polymyxin B Sul-Trimethoprim | 295 | 228 |
| Difluprednate | 229 | 150 |
| Timolol Maleate | 184 | 56 |
| Bimatoprostbrand: Lumigan | 152 | 33 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$293 across 5 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-02-09
- Last updated
- 2010-07-13
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.